Bayer Spotlights Innovations to Address Rising Health Challenges in the Asia Pacific Region

Bayer reinforced its commitment to advancing healthcare solutions for patients in the APAC region with very diverse healthcare landscapes and varying patient needs

- 

(Ashraf Al-Ouf)

“By 2050, heart failure cases in the Asia-Pacific region are projected to reach 74.5 million, a staggering 127.6% increase from 2025,” stated Ashraf Al-Ouf, Head of Pharmaceutical Commercial Operations markets in Asia-Pacific at Bayer. “Amid these concerning projections, we are poised to address healthcare needs and bring new therapeutic options for patients across countries in East Asia, South Asia, Southeast Asia, and Oceania.” In addition to Cardiovascular Diseases, Bayer is well positioned to tackle a range of healthcare challenges. Its product portfolio for the APAC markets includes therapies in areas such as Oncology, Ophthalmology, Women’s Health, and Radiology.

In addition, the company is accelerating its momentum through pharmaceutical innovation and clinical research. Currently, Bayer is conducting 34 ongoing clinical trials in APAC, demonstrating its dedication to advancing medical research and improving patient outcomes. Besides, the company has established two life science incubators in Asia: Bayer Co.Lab Kobe and Bayer Co.Lab Shanghai, which is the largest co-creation incubator in APAC. They are focused on fostering and promoting early-stage biotech innovation in areas such as Cell and Gene Therapy and Oncology.